CA2360796A1 - Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique - Google Patents

Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique Download PDF

Info

Publication number
CA2360796A1
CA2360796A1 CA002360796A CA2360796A CA2360796A1 CA 2360796 A1 CA2360796 A1 CA 2360796A1 CA 002360796 A CA002360796 A CA 002360796A CA 2360796 A CA2360796 A CA 2360796A CA 2360796 A1 CA2360796 A1 CA 2360796A1
Authority
CA
Canada
Prior art keywords
helper
packaging signal
virus
adenovirus
dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002360796A
Other languages
English (en)
Inventor
Andrew Bett
Volker Sandig
Rima Youil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2360796A1 publication Critical patent/CA2360796A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des éléments vecteurs adénoviraux dépendant d'un assistant ainsi que des éléments d'adénovirus assistant qui favorisent la production et l'isolement de vecteurs adénoviraux dépendant d'un assistant. De tels éléments comprennent un signal d'encapsidation présentant une faible homologie avec un signal d'encapsidation de type sauvage, et de préférence une activité réduite par rapport à ce dernier, un segment non codant E4 lié directement à 5' ITR qui confère un avantage sélectif, et une ou des régions stuffer qui fournissent un vecteur adénoviral dépendant d'un assistant avec une teneur en GC de 50 à 60 % environ. Le signal d'encapsidation modifié sert de préférence à diminuer la recombinaison et la production de virus. Le segment E4 non codant et la ou les régions stuffer sont utilisés de préférence dans un vecteur adénoviral assistant-dépendant d'un assistant pour conférer à ce vecteur un avantage de croissance sur le virus assistant.
CA002360796A 1999-02-04 2000-01-31 Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique Abandoned CA2360796A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11860199P 1999-02-04 1999-02-04
US60/118,601 1999-02-04
US13813499P 1999-06-08 1999-06-08
US60/138,134 1999-06-08
PCT/US2000/002405 WO2000046360A1 (fr) 1999-02-04 2000-01-31 Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique

Publications (1)

Publication Number Publication Date
CA2360796A1 true CA2360796A1 (fr) 2000-08-10

Family

ID=26816557

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360796A Abandoned CA2360796A1 (fr) 1999-02-04 2000-01-31 Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique

Country Status (4)

Country Link
EP (1) EP1151091A4 (fr)
JP (1) JP2002535986A (fr)
CA (1) CA2360796A1 (fr)
WO (1) WO2000046360A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081707A1 (en) * 2000-06-29 2002-06-27 Donna Armentano Methods for helper-dependent adenoviral vector production
US7820441B2 (en) 2000-09-25 2010-10-26 The Regents Of The University Of Michigan Production of viral vectors
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
US20100173387A1 (en) * 2006-04-28 2010-07-08 Universitat Autonoma De Barcelona Method for producing adenovirus vectors for gene therapy and dna sequences used therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080569A (en) * 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6228646B1 (en) * 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
EP0954579A1 (fr) * 1996-06-20 1999-11-10 Merck & Co., Inc. Therapie genique pour le traitement de l'obesite

Also Published As

Publication number Publication date
WO2000046360A1 (fr) 2000-08-10
JP2002535986A (ja) 2002-10-29
EP1151091A4 (fr) 2002-09-04
EP1151091A1 (fr) 2001-11-07

Similar Documents

Publication Publication Date Title
Chartier et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
Fisher et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis
US5922576A (en) Simplified system for generating recombinant adenoviruses
Parks et al. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging
JP4495588B2 (ja) 安定なアデノウイルスベクターおよびその増殖方法
EP0988389B1 (fr) Procede de production de vecteurs adenoviraux n'appartenant pas au groupe c
US5700470A (en) Recombinant adenovirus with removed EZA gene and method of preparation
WO1999053089A1 (fr) Vecteur de transfert genique d'adenovirus recombinant
US8088621B2 (en) Adenoviral fiber exchange shuttle system
US7132277B1 (en) Helper dependent vector system for gene therapy
CA2360796A1 (fr) Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique
Grave et al. Differential influence of the E4 adenoviral genes on viral and cellular promoters
Hartigan-O'Connor et al. Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection
US20040198683A1 (en) Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
JP6795530B2 (ja) 大きな核酸をクローニングするためのアデノウイルスベクターを作製する手段
Zhang et al. A novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expression
Hokanson et al. Hybrid yeast–bacteria cloning system used to capture and modify adenoviral and nonviral genomes
Magalhães et al. An adenovirus vector containing the suicide gene thymidine kinase for a broad application in cancer gene therapy
US6740515B1 (en) Recombinant adenovirus
US20020001579A1 (en) Nonhuman helper-dependent virus vector
JP3713038B2 (ja) 組換えアデノウイルス

Legal Events

Date Code Title Description
FZDE Dead